Womens Health Diagnostic Test MarketSize and Trends

Initiative taken by a health organization in prevention measures of chronic diseases and introduction of rapid diagnostic tests is expected to propel the market growth

Growing demand for early stage diagnosis of infection/diseases needs new rapid diagnostic tests and imaging system which is expected to fuel the growth of Womens Health Diagnostic Test Market in the near future.

Increasing prevalence of chronic diseases among women and rising awareness program is expected to fuel the growth of women’s health diagnostic test market

Increasing incidence and prevalence of chronic diseases among women and demand for accurate and precise diagnostics are the major factors expected to augment the growth of woman’s health diagnostics market during the forecast period.

Furthermore, according to the Centers for Disease Control and Prevention (CDC), in 2015, around 3,978,497 new born were estimated, which supports the increasing pregnancy cases and demand for various gestation and fertility tests and treatments, which is one of the major factors expected to propel growth of women’s health diagnostic test market in the near future.

Key Developments in Women’s Health Diagnostic Test Market

In May 2019, Qiagen N.V. launched first U.S. FDA-approved companion diagnostic test, Therascreen PIK3CA Kit, for identifying breast cancer patients.
In January 2019, Nurx Inc. launched At-Home HPV Test Kits to detect the types of human papillomavirus (HPV) that are commonly found in cervical cancer.
In September 2018, Mira, a part of Quanovate Tech Inc, launched Mira Fertility system personalized cycle prediction by measuring fertility hormone concentrations in urine samples. The devices also helps the women to know their fertility status.
In December 2017, Inito, a medical technology startup, launched a fertility monitor that helps women to track their ovulation days at home in an easy and convenient way. The device enables smartphones to perform lab-grade medical diagnostic tests at home using a single portable device.
In September 2017, GE Healthcare received U.S. FDA 510 (k) clearance for it’s first-ever mammography system. The device allows women to manage their own compression during the mammography exam with the help of company’s proprietary Senographe Pristina Dueta, a remote control.